Provided by Tiger Trade Technology Pte. Ltd.

Prestige

62.32
+0.72001.17%
Post-market: 62.320.00000.00%16:32 EST
Volume:412.22K
Turnover:25.73M
Market Cap:3.00B
PE:15.42
High:62.92
Open:61.63
Low:61.40
Close:61.60
52wk High:90.04
52wk Low:57.25
Shares:48.08M
Float Shares:48.08M
Volume Ratio:1.04
T/O Rate:0.86%
Dividend:- -
Dividend Rate:- -
EPS(TTM):4.04
EPS(LYR):4.32
ROE:11.29%
ROA:6.37%
PB:1.64
PE(LYR):14.43

Loading ...

Corrected-Prestige Consumer Healthcare Outlook FY Organic Growth -3 to -1.5%

THOMSON REUTERS
·
Nov 06

Prestige Consumer Healthcare Q2 Operating Expenses USD 71.909 Million

THOMSON REUTERS
·
Nov 06

Prestige Consumer Healthcare Inc. Reports Second Quarter and First Half Fiscal 2026 Results

THOMSON REUTERS
·
Nov 06

Shiseido Names Yoshiaki Okabe Chief Marketing and Innovation Officer

Reuters
·
Nov 05

RBC Capital Keeps Their Buy Rating on Premium Brands (PBH)

TIPRANKS
·
Nov 05

Prestige Biopharma Secures Raw Material Supply Deal from Russia-based Pharmapark

MT Newswires Live
·
Nov 03

Prestige Consumer Healthcare (PBH): Examining Valuation as Earnings Expectations Weigh on Sentiment

Simply Wall St.
·
Nov 02

TTK Prestige Announces Q2 and Half-Year Financial Results

TIPRANKS
·
Oct 29

ICICI Securities Upgrades TTK Prestige to Add from Hold, Price Target is INR760

MT Newswires Live
·
Oct 29

Prestige International Announces Treasury Stock Repurchase Plan

TIPRANKS
·
Oct 29

Prestige International 1H Net Y2.66B Vs Net Y2.23B

Dow Jones
·
Oct 29

TTK Prestige's Consolidated Profit Rises in Fiscal Q2

MT Newswires Live
·
Oct 28

MBX Biosciences Advances Phase 2a Study on PBH Treatment with Imapextide

TIPRANKS
·
Oct 28

Prestige Consumer Hlthcr Is Maintained at Hold by Jefferies

Dow Jones
·
Oct 27

Prestige Consumer Healthcare Inc : Jefferies Cuts Target Price to $71 From $75

THOMSON REUTERS
·
Oct 27

The Bull Case for Prestige Consumer Healthcare (PBH) Could Change Following Reduced Guidance and Supply Chain Challenges

Simply Wall St.
·
Oct 27

Why Prestige Consumer Healthcare's Outlook Looks Unhealthy

Benzinga_recent_news
·
Oct 22

Oppenheimer Cuts Price Target on Prestige Consumer Healthcare to $72 From $82, Keeps Outperform Rating

MT Newswires Live
·
Oct 21

Teva Reaches License Deal With Prestige Biopharma for Cancer Medication in Europe

Dow Jones
·
Oct 21

Teva enters Tuznue license agreement with Prestige Biopharma

TIPRANKS
·
Oct 21